The World Mitochondria Society awarded Poxel for its results about Imeglimin, a new mitochondria-targeted agent for type 2 Diabetes treatment
POXEL SA, a biopharmaceutical company developing innovative drugs to treat type 2 diabetes today presented some preclinical data on Imeglimin, the Company’s first-in-class oral anti-diabetic agent, at the 6th World Congress on Targeting Mitochondria held October 28-30, 2015, in Berlin, Germany.
Imeglimin has been proven to have a beneficial effect on both insulin sensitizing and insulin secretion defects in type 2 diabetes. The new data demonstrate the drug candidate’s positive impact on the mitochondrial respiratory chain, providing critical insights to Imeglimin’s molecular mechanism of action. “These results clearly demonstrate Imeglimin’s innovative mechanism of action and illustrate the benefits of targeting the mitochondria to treat type 2 diabetes,” said Sébastien Bolze, Ph.D., EVP Non-Clinical Development and CSO of Poxel. ”Our data confirm again that Imeglimin’s profile is unique among current anti-diabetic agents.”
About Poxel
Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has entered clinical development in Japanese subjects. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development.
